The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1411
Misoprostol for Miscarriage
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Misoprostol (Cytotec, and generics), a prostaglandin E1 analog FDA-approved for prevention of NSAID-induced gastric ulcers1 and, when taken with mifepristone (Mifeprex), for termination of early intrauterine pregnancy,2 has also been used off-label for years for medical management of first-trimester spontaneous abortion (miscarriage).

SPONTANEOUS ABORTION — Miscarriage occurs in about 10-15% of pregnancies.3 For women with an incomplete or missed first-trimester miscarriage documented by an ultrasound, the gestational sac can be removed by suction curettage or medical treatment with misoprostol. Some women, given a choice, elect expectant management rather than surgical or medical intervention; in one study, 70% of untreated women completed their miscarriage within 14 days ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Misoprostol for Miscarriage
Article code: 1411b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian